Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balch, C. M.
Right arrow Articles by Morabito, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balch, C. M.
Right arrow Articles by Morabito, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 16 (August), 2001: 3622-3634
© 2001 American Society for Clinical Oncology

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

By Charles M. Balch, Seng-Jaw Soong, Jeffrey E. Gershenwald, John F. Thompson, Douglas S. Reintgen, Natale Cascinelli, Marshall Urist, Kelly M. McMasters, Merrick I. Ross, John M. Kirkwood, Michael B. Atkins, John A. Thompson, Daniel G. Coit, David Byrd, Renee Desmond, Yuting Zhang, Ping-Yu Liu, Gary H. Lyman, Aberto Morabito

From the Johns Hopkins Medical Institutions, Baltimore, MD; American Society of Clinical Oncology, Alexandria, VA; University of Alabama at Birmingham, Birmingham, AL; University of Texas, M.D. Anderson Cancer Center, Houston, TX; Sydney Melanoma Unit, University of Sydney, Sydney, New South Wales, Australia; H. Lee Moffit Cancer Center, University of South Florida, Tampa, FL; Istituto Nazionale Tumori, World Health Organization Melanoma Program, Milan, Italy; University of Louisville Medical Center, Louisville, KY; University of Pittsburgh Medical Center, Pittsburgh, PA; Beth Israel Deaconess Medical Center, Boston, MA; University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; and Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Charles M. Balch, MD, American Society of Clinical Oncology, 1900 Duke St, Ste 200, Alexandria, VA 22314; email: balchc{at}asco.org

PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,450 melanoma patients from their databases in order to validate this staging proposal.

PATIENTS AND METHODS: There were 17,600 melanoma patients with complete clinical, pathologic, and follow-up information. Factors predicting melanoma-specific survival rates were analyzed using the Cox proportional hazards regression model. Follow-up survival data for 5 years or longer were available for 73% of the patients.

RESULTS: This analysis demonstrated that (1) in the T category, tumor thickness and ulceration were the most powerful predictors of survival, and the level of invasion had a significant impact only within the subgroup of thin (<= 1 mm) melanomas; (2) in the N category, the following three independent factors were identified: the number of metastatic nodes, whether nodal metastases were clinically occult or clinically apparent, and the presence or absence of primary tumor ulceration; and (3) in the M category, nonvisceral metastases was associated with a better survival compared with visceral metastases. A marked diversity in the natural history of pathologic stage III melanoma was demonstrated by five-fold differences in 5-year survival rates for defined subgroups. This analysis also demonstrated that large and complex data sets could be used effectively to examine prognosis and survival outcome in melanoma patients.

CONCLUSION: The results of this evidence-based methodology were incorporated into the AJCC melanoma staging as described in the companion publication.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. A. Pollitt, A. C. Geller, D. R. Brooks, T. M. Johnson, E. R. Park, and S. M. Swetter
Efficacy of Skin Self-Examination Practices for Early Melanoma Detection
Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 3018 - 3023.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. A. Voit, A. C.J. van Akkooi, G. Schafer-Hesterberg, A. Schoengen, P. I.M. Schmitz, W. Sterry, and A. M.M. Eggermont
Rotterdam Criteria for Sentinel Node (SN) Tumor Burden and the Accuracy of Ultrasound (US) -Guided Fine-Needle Aspiration Cytology (FNAC): Can US-Guided FNAC Replace SN Staging in Patients With Melanoma?
J. Clin. Oncol., October 20, 2009; 27(30): 4994 - 5000.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. C. Lee, M. B. Faries, L. A. Wanek, and D. L. Morton
Improved Survival for Stage IV Melanoma From an Unknown Primary Site
J. Clin. Oncol., July 20, 2009; 27(21): 3489 - 3495.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
C. M. Intenzo, C. A. Truluck, M. C. Kushen, S. M. Kim, A. Berger, and J. C. Kairys
Lymphoscintigraphy in Cutaneous Melanoma: An Updated Total Body Atlas of Sentinel Node Mapping1
RadioGraphics, July 1, 2009; 29(4): 1125 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, C. Coens, S. Suciu, M. Santinami, W. Kruit, A. Testori, J. Marsden, C. Punt, F. Sales, M. Gore, et al.
Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
J. Clin. Oncol., June 20, 2009; 27(18): 2916 - 2923.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Glaspy, A. Ribas, and B. Chmielowski
Interferon Alfa in the Postsurgical Management of High-Risk Melanoma: Is It Worth It?
J. Clin. Oncol., June 20, 2009; 27(18): 2896 - 2897.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. G. Bouwhuis, S. Suciu, S. Collette, S. Aamdal, W. H. Kruit, L. Bastholt, U. Stierner, F. Sales, P. Patel, C. J. A. Punt, et al.
Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon
J Natl Cancer Inst, June 16, 2009; 101(12): 869 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. J. Sneyd and B. Cox
Melanoma in Maori, Asian, and Pacific Peoples in New Zealand
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1706 - 1713.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Findeisen, M. Zapatka, T. Peccerella, H. Matzk, M. Neumaier, D. Schadendorf, and S. Ugurel
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling
J. Clin. Oncol., May 1, 2009; 27(13): 2199 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. Chen, I. Osman, and S. J. Orlow
Antifolate Activity of Pyrimethamine Enhances Temozolomide-Induced Cytotoxicity in Melanoma Cells
Mol. Cancer Res., May 1, 2009; 7(5): 703 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Z. Li, R. Zhou, H. N. Xu, L. Moon, T. Zhong, E. J. Kim, H. Qiao, R. Reddy, D. Leeper, B. Chance, et al.
Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential
PNAS, April 21, 2009; 106(16): 6608 - 6613.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. M. Swetter, T. M. Johnson, D. R. Miller, C. J. Layton, K. R. Brooks, and A. C. Geller
Melanoma in Middle-aged and Older Men: A Multi-institutional Survey Study of Factors Related to Tumor Thickness
Arch Dermatol, April 1, 2009; 145(4): 397 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
P. T. Bradford, A. M. Goldstein, M. L. McMaster, and M. A. Tucker
Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005
Arch Dermatol, April 1, 2009; 145(4): 427 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. D. Davis, B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al.
Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Clin. Cancer Res., March 15, 2009; 15(6): 2123 - 2129.
[Abstract] [Full Text] [PDF]

Home page
 In VivoHome page
F. DI FILIPPO, P. GIACOMINI, C.R. ROSSI, M. SANTINAMI, M. ANZA, R. GARINEI, P. PERRI, C. BOTTI, P. DI ANGELO, C. SOFRA, et al.
Prognostic Factors Influencing Tumor Response, Locoregional Control and Survival, in Melanoma Patients with Multiple Limb In-transit Metastases Treated with TNF{alpha}-based Isolated Limb Perfusion
In Vivo, March 1, 2009; 23(2): 347 - 352.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Pectasides, U. Dafni, D. Bafaloukos, D. Skarlos, A. Polyzos, D. Tsoutsos, H. Kalofonos, G. Fountzilas, P. Panagiotou, G. Kokkalis, et al.
Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
J. Clin. Oncol., February 20, 2009; 27(6): 939 - 944.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. N. Lopez, C. Pereda, G. Segal, L. Munoz, R. Aguilera, F. E. Gonzalez, A. Escobar, A. Ginesta, D. Reyes, R. Gonzalez, et al.
Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor {beta}-Expressing T Cells
J. Clin. Oncol., February 20, 2009; 27(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. C. Lee, M. B. Faries, and D. L. Morton
In Reply
J. Clin. Oncol., February 20, 2009; 27(6): 999 - 999.
[Full Text] [PDF]

Home page
 JCOHome page
H. Stensheim, B. Moller, T. van Dijk, and S. D. Fossa
Cause-Specific Survival for Women Diagnosed With Cancer During Pregnancy or Lactation: A Registry-Based Cohort Study
J. Clin. Oncol., January 1, 2009; 27(1): 45 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Wagner, C. Krepler, D. Allwardt, J. Latzka, S. Strommer, O. Scheiner, H. Pehamberger, U. Wiedermann, C. Hafner, and H. Breiteneder
Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine
Clin. Cancer Res., December 15, 2008; 14(24): 8178 - 8183.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Manca, A. Romanini, D. Pellegrino, E. Borso, M. Rondini, C. Orlandini, V. Zucchi, F. Pasqualetti, and G. Mariani
Optimal Detection of Sentinel Lymph Node Metastases by Intraoperative Radioactive Threshold and Molecular Analysis in Patients with Melanoma
J. Nucl. Med., November 1, 2008; 49(11): 1769 - 1775.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Gershenwald, R. H.I. Andtbacka, V. G. Prieto, M. M. Johnson, A. H. Diwan, J. E. Lee, P. F. Mansfield, J. N. Cormier, C. W. Schacherer, and M. I. Ross
Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma
J. Clin. Oncol., September 10, 2008; 26(26): 4296 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
A. C. Federico, A. B. Chagpar, M. I. Ross, R. C. G. Martin, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, J. J. Sussman, et al.
Effect of Multiple-Nodal Basin Drainage on Cutaneous Melanoma
Arch Surg, July 1, 2008; 143(7): 632 - 638.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Li, M. Martinka, and G. Li
Role of ING4 in human melanoma cell migration, invasion and patient survival
Carcinogenesis, July 1, 2008; 29(7): 1373 - 1379.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Garbe, P. Radny, R. Linse, R. Dummer, R. Gutzmer, J. Ulrich, R. Stadler, M. Weichenthal, TK. Eigentler, U. Ellwanger, et al.
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
Ann. Onc., June 1, 2008; 19(6): 1195 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. M. Kreizenbeck, A. J. Berger, A. Subtil, D. L. Rimm, and B. E. Gould Rothberg
Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma
Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 949 - 958.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
F. Niakosari, H. J. Kahn, D. McCready, D. Ghazarian, L. E. Rotstein, A. Marks, A. Kiss, and L. From
Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration: Predictors of Sentinel Lymph Node Involvement in Primary Cutaneous Melanoma
Arch Dermatol, April 1, 2008; 144(4): 462 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. de Vries, T. E. C. Nijsten, O. Visser, E. Bastiaannet, S. van Hattem, M. L. Janssen-Heijnen, and J. -W. W. Coebergh
Superior survival of females among 10 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site
Ann. Onc., March 1, 2008; 19(3): 583 - 589.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Kaur, R J Thomas, N Desai, M A Green, D Lovell, B W E M Powell, and M G Cook
The correlation of regression in primary melanoma with sentinel lymph node status
J. Clin. Pathol., March 1, 2008; 61(3): 297 - 300.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Korn, P.-Y. Liu, S. J. Lee, J.-A. W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al.
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
J. Clin. Oncol., February 1, 2008; 26(4): 527 - 534.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch and S.-j. Soong
Predicting Outcomes in Metastatic Melanoma
J. Clin. Oncol., January 10, 2008; 26(2): 168 - 169.
[Full Text] [PDF]

Home page
 JCOHome page
J. A. Zell, P. Cinar, M. Mobasher, A. Ziogas, F. L. Meyskens Jr, and H. Anton-Culver
Survival for Patients With Invasive Cutaneous Melanoma Among Ethnic Groups: The Effects of Socioeconomic Status and Treatment
J. Clin. Oncol., January 1, 2008; 26(1): 66 - 75.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Lengagne, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.-G. Guillet, V. H. Engelhard, M.-F. Avril, J.-P. Abastado, and A. Prevost-Blondel
Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases
J. Immunol., January 1, 2008; 180(1): 130 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. K. Haass, K. Sproesser, T. K. Nguyen, R. Contractor, C. A. Medina, K. L. Nathanson, M. Herlyn, and K. S.M. Smalley
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
Clin. Cancer Res., January 1, 2008; 14(1): 230 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. R. Lange and C. M. Balch
Melanoma in Older Patients
ASCO Educational Book, January 1, 2008; 2008(1): 399 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al.
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting
Clin. Cancer Res., November 1, 2007; 13(21): 6386 - 6395.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. Rao, R. A. Sayeed, S. Tomaszek, S. Fischer, S. Keshavjee, and G. E. Darling
Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer
Ann. Thorac. Surg., September 1, 2007; 84(3): 934 - 939.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Kaae, J. Wohlfahrt, H. A. Boyd, H. C. Wulf, R. J. Biggar, and M. Melbye
The Impact of Autoimmune Diseases on the Incidence and Prognosis of Cutaneous Malignant Melanoma
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1840 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
W. Hofstetter, A. M. Correa, N. Bekele, J. A. Ajani, A. Phan, R. R. Komaki, Z. Liao, D. Maru, T. T. Wu, R. J. Mehran, et al.
Proposed Modification of Nodal Status in AJCC Esophageal Cancer Staging System
Ann. Thorac. Surg., August 1, 2007; 84(2): 365 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
C. A. Reyes Ortiz, J. L. Freeman, Y.-F. Kuo, and J. S. Goodwin
The Influence of Marital Status on Stage at Diagnosis and Survival of Older Persons With Melanoma
J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 892 - 898.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
K. B. Stitzenberg, N. E. Thomas, K. Dalton, S. E. Brier, D. W. Ollila, M. Berwick, D. Mattingly, and R. C. Millikan
Distance to Diagnosing Provider as a Measure of Access for Patients With Melanoma
Arch Dermatol, August 1, 2007; 143(8): 991 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
J. K. Wall, M. Florero, N. A. Accortt, R. Allen, M. Kashani-Sabet, E. Morita, and S. P. L. Leong
Impact of Multiple Lymphatic Channel Drainage to a Single Nodal Basin on Outcomes in Melanoma
Arch Surg, August 1, 2007; 142(8): 753 - 758.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. R. Bradford and P. A. Levine
Incidence and Prognosis of Cutaneous Melanoma Involving the Head and Neck
JAMA, June 20, 2007; 297(23): 2628 - 2629.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. D. Davis, B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. H. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, et al.
An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Clin. Cancer Res., June 15, 2007; 13(12): 3630 - 3636.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. N. Cormier, Y. Xing, M. Ding, S. B. Cantor, K. J. Salter, J. E. Lee, P. F. Mansfield, J. E. Gershenwald, and M. I. Ross
Cost Effectiveness of Adjuvant Interferon in Node-Positive Melanoma
J. Clin. Oncol., June 10, 2007; 25(17): 2442 - 2448.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E de Vries, S Houterman, M. Janssen-Heijnen, T Nijsten, S. van de Schans, A. Eggermont, and J. Coebergh
Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands
Ann. Onc., June 1, 2007; 18(6): 1110 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Azuma, Y. Ishikawa, S. Kawai, T. Tsunenari, H. Tsunoda, T. Igawa, S.-i. Iida, M. Nanami, M. Suzuki, R. F. Irie, et al.
Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma
Clin. Cancer Res., May 1, 2007; 13(9): 2745 - 2750.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Mocellin, D. S.B. Hoon, P. Pilati, C. R. Rossi, and D. Nitti
Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis
J. Clin. Oncol., April 20, 2007; 25(12): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani
Toward a Molecular Classification of Melanoma
J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Balakrishnan, F. E. Bleeker, S. Lamba, M. Rodolfo, M. Daniotti, A. Scarpa, A. A. van Tilborg, S. Leenstra, C. Zanon, and A. Bardelli
Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma
Cancer Res., April 15, 2007; 67(8): 3545 - 3550.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M. L. Pennie, S. L. Soon, J. B. Risser, E. Veledar, S. D. Culler, and S. C. Chen
Melanoma Outcomes for Medicare Patients: Association of Stage and Survival With Detection by a Dermatologist vs a Nondermatologist
Arch Dermatol, April 1, 2007; 143(4): 488 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. N. Markovic, L. A. Erickson, R. D. Rao, R. H. Weenig, B. A. Pockaj, A. Bardia, C. M. Vachon, S. E. Schild, R. R. McWilliams, J. L. Hand, et al.
Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment
Mayo Clin. Proc., April 1, 2007; 82(4): 490 - 513.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Gimotty, D. E. Elder, D. L. Fraker, J. Botbyl, K. Sellers, R. Elenitsas, M. E. Ming, L. Schuchter, F. R. Spitz, B. J. Czerniecki, et al.
Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas
J. Clin. Oncol., March 20, 2007; 25(9): 1129 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. C. Taylor, A. Patel, K. S. Panageas, K. J. Busam, and M. S. Brady
Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma
J. Clin. Oncol., March 1, 2007; 25(7): 869 - 875.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. M. Thomas, R. P. A'Hern, J. M. Grichnik, S. Retsas, D. Lipsker, M. H. Kanzler, L. Levitt, A. Lin, D. L. Morton, A. J. Cochran, et al.
Sentinel-Node Biopsy in Melanoma
N. Engl. J. Med., January 25, 2007; 356(4): 418 - 421.
[Full Text] [PDF]

Home page
 JNMHome page
Y. Miao, K. Benwell, and T. P. Quinn
99mTc- and 111In-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection
J. Nucl. Med., January 1, 2007; 48(1): 73 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. M. Swetter, S. Soon, C. R. Harrington, and S. C. Chen
Effect of Health Care Delivery Models on Melanoma Thickness and Stage in a University-Based Referral Center: An Observational Pilot Study
Arch Dermatol, January 1, 2007; 143(1): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
J. K. Robinson, R. Turrisi, and J. Stapleton
Efficacy of a Partner Assistance Intervention Designed to Increase Skin Self-examination Performance
Arch Dermatol, January 1, 2007; 143(1): 37 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
F. Tas, S. Kurul, H. Camlica, and E. Topuz
Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases
Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 794 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
W. Liu, J. P. Dowling, W. K. Murray, G. A. McArthur, J. F. Thompson, R. Wolfe, and J. W. Kelly
Rate of Growth in Melanomas: Characteristics and Associations of Rapidly Growing Melanomas
Arch Dermatol, December 1, 2006; 142(12): 1551 - 1558.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H Gogas, A Polyzos, I Stavrinidis, K Frangia, D Tsoutsos, P Panagiotou, C Markopoulos, O Papadopoulos, D Pectasides, M Mantzourani, et al.
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group
Ann. Onc., December 1, 2006; 17(12): 1835 - 1841.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Rangel, S. Torabian, L. Shaikh, M. Nosrati, F. L. Baehner, C. Haqq, S. P.L. Leong, J. R. Miller III, R. W. Sagebiel, and M. Kashani-Sabet
Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma
J. Clin. Oncol., October 1, 2006; 24(28): 4565 - 4569.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. van Akkooi, J. de Wilt, C Verhoef, P. Schmitz, A. van Geel, A. Eggermont, and M Kliffen
Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?
Ann. Onc., October 1, 2006; 17(10): 1578 - 1585.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. L. Morton, J. F. Thompson, A. J. Cochran, N. Mozzillo, R. Elashoff, R. Essner, O. E. Nieweg, D. F. Roses, H. J. Hoekstra, C. P. Karakousis, et al.
Sentinel-node biopsy or nodal observation in melanoma.
N. Engl. J. Med., September 28, 2006; 355(13): 1307 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. M. Balch and N. Cascinelli
Sentinel-Node Biopsy in Melanoma
N. Engl. J. Med., September 28, 2006; 355(13): 1370 - 1371.
[Full Text] [PDF]

Home page
 JCOHome page
N. Cascinelli, E. Bombardieri, R. Bufalino, T. Camerini, A. Carbone, C. Clemente, L. Lenisa, L. Mascheroni, A. Maurichi, E. Pennacchioli, et al.
Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival
J. Clin. Oncol., September 20, 2006; 24(27): 4464 - 4471.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
R. Essner, R. Scheri, M. Kavanagh, H. Torisu-Itakura, L. A. Wanek, and D. L. Morton
Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection
Arch Surg, September 1, 2006; 141(9): 877 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
H. Kittler, P. Guitera, E. Riedl, M. Avramidis, L. Teban, M. Fiebiger, R. A. Weger, M. Dawid, and S. Menzies
Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging.
Arch Dermatol, September 1, 2006; 142(9): 1113 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Campillo, J. A. Martinez-Escribano, M. R. Moya-Quiles, L. A. Marin, M. Muro, N. Guerra, A. Parrado, M. Campos, J. F. Frias, A. Minguela, et al.
Natural Killer Receptors on CD8 T Cells and Natural Killer Cells from Different HLA-C Phenotypes in Melanoma Patients.
Clin. Cancer Res., August 15, 2006; 12(16): 4822 - 4831.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mocellin, D. Hoon, A. Ambrosi, D. Nitti, and C. R. Rossi
The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis
Clin. Cancer Res., August 1, 2006; 12(15): 4605 - 4613.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. J. Miller and M. C. Mihm Jr.
Melanoma.
N. Engl. J. Med., July 6, 2006; 355(1): 51 - 65.
[Full Text] [PDF]

Home page
 JCOHome page
S. J. Moschos, H. D. Edington, S. R. Land, U. N. Rao, D. Jukic, J. Shipe-Spotloe, and J. M. Kirkwood
Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
J. Clin. Oncol., July 1, 2006; 24(19): 3164 - 3171.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al.
Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma
J. Clin. Oncol., June 20, 2006; 24(18): 2849 - 2857.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Aloia, J. E. Gershenwald, R. H. Andtbacka, M. M. Johnson, C. W. Schacherer, C. S. Ng, J. N. Cormier, J. E. Lee, M. I. Ross, and P. F. Mansfield
Utility of Computed Tomography and Magnetic Resonance Imaging Staging Before Completion Lymphadenectomy in Patients With Sentinel Lymph Node-Positive Melanoma
J. Clin. Oncol., June 20, 2006; 24(18): 2858 - 2865.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
J. Nucl. Med., June 1, 2006; 47(6): 957 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. S. Reddy, S. Ganesh, and D.-C. Yu
Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses.
Clin. Cancer Res., May 1, 2006; 12(9): 2869 - 2878.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. Kakinuma and S. T. Hwang
Chemokines, chemokine receptors, and cancer metastasis
J. Leukoc. Biol., April 1, 2006; 79(4): 639 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Schadendorf, S. Ugurel, B. Schuler-Thurner, F. O. Nestle, A. Enk, E.-B. Brocker, S. Grabbe, W. Rittgen, L. Edler, A. Sucker, et al.
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
Ann. Onc., April 1, 2006; 17(4): 563 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. I. Ross
Early-stage melanoma: staging criteria and prognostic modeling.
Clin. Cancer Res., April 1, 2006; 12(7): 2312s - 2319s.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
D. L. Cummins, J. M. Cummins, H. Pantle, M. A. Silverman, A. L. Leonard, and A. Chanmugam
Cutaneous Malignant Melanoma
Mayo Clin. Proc., April 1, 2006; 81(4): 500 - 507.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. M. Shaw, M. J. Quinn, R. A. Scolyer, and J. F. Thompson
Survival in Patients With Desmoplastic Melanoma
J. Clin. Oncol., March 10, 2006; 24(8): e12 - e12.
[Full Text] [PDF]

Home page
 JCOHome page
D. P. Livestro, A. Sober, and K. K. Tanabe
In Reply:
J. Clin. Oncol., March 10, 2006; 24(8): e13 - e13.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Reinhardt, A. Y. Joe, U. Jaeger, A. Huber, A. Matthies, J. Bucerius, R. Roedel, H. Strunk, T. Bieber, H.-J. Biersack, et al.
Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients
J. Clin. Oncol., March 1, 2006; 24(7): 1178 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Dummer, C. Garbe, J. A. Thompson, A. M. Eggermont, K. Yoo, T. Maier, and B. Bergstrom
Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma
J. Clin. Oncol., March 1, 2006; 24(7): 1188 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, et al.
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
N. Engl. J. Med., February 16, 2006; 354(7): 709 - 718.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Schmidt, J. S. Johansen, P. Sjoegren, I. J. Christensen, B. S. Sorensen, K. Fode, J. Larsen, and H. von der Maase
Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma
J. Clin. Oncol., February 10, 2006; 24(5): 798 - 804.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. F. Uren
Sentinel Lymph Node Biopsy in Melanoma
J. Nucl. Med., February 1, 2006; 47(2): 191 - 195.
[Full Text] [PDF]

Home page
 JCOHome page
D. Berd, M. J. Mastrangelo, and T. Sato
Calculation of Survival of Patients With Stage III Melanoma
J. Clin. Oncol., December 20, 2005; 23(36): 9427 - 9427.
[Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch, S.-J. Soong, and R. Desmond
In Reply:
J. Clin. Oncol., December 20, 2005; 23(36): 9428 - 9428.
[Full Text] [PDF]

Home page
 JCOHome page
R. W. Weber, S. O'Day, M. Rose, R. Deck, P. Ames, J. Good, J. Meyer, R. Allen, S. Trautvetter, M. Timmerman, et al.
Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-{alpha}2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma
J. Clin. Oncol., December 10, 2005; 23(35): 8992 - 9000.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Kirkwood
Building Upon the Standard of Care in Adjuvant Therapy of High-Risk Melanoma
J. Clin. Oncol., December 1, 2005; 23(34): 8559 - 8563.
[Full Text] [PDF]

Home page
 JCOHome page
P. A. Gimotty, P. Van Belle, D. E. Elder, T. Murry, K. T. Montone, X. Xu, S. Hotz, S. Raines, M. E. Ming, P. Wahl, et al.
Biologic and Prognostic Significance of Dermal Ki67 Expression, Mitoses, and Tumorigenicity in Thin Invasive Cutaneous Melanoma
J. Clin. Oncol., November 1, 2005; 23(31): 8048 - 8056.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online